[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 71 pages | ID: H7FF057B200EEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Drugs In Development, 2022, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 1, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 3 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hepatitis D - Overview
Hepatitis D - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis D - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis D - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Antios Therapeutics Inc
CN Bio Innovations Ltd
Eiger BioPharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Globeimmune Inc
Huahui Anjian (Beijing) Biotechnology Co Ltd
Johnson & Johnson
Merck & Co Inc
PharmaEssentia Corp
Replicor Inc
Rodos BioTarget GmbH
SomaGenics Inc
Svenska Vaccinfabriken Produktion AB
Vir Biotechnology Inc
Hepatitis D - Drug Profiles
A-2342 - Drug Profile
Product Description
Mechanism Of Action
Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATI-2173 - Drug Profile
Product Description
Mechanism Of Action
History of Events
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
History of Events
daplusiran - Drug Profile
Product Description
Mechanism Of Action
History of Events
GI-18000 - Drug Profile
Product Description
Mechanism Of Action
HH-003 - Drug Profile
Product Description
Mechanism Of Action
HH-006 - Drug Profile
Product Description
Mechanism Of Action
lonafarnib - Drug Profile
Product Description
Mechanism Of Action
History of Events
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
History of Events
peginterferon lambda-1a - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBT-05 - Drug Profile
Product Description
Mechanism Of Action
History of Events
REP-2139 - Drug Profile
Product Description
Mechanism Of Action
History of Events
REP-2165 - Drug Profile
Product Description
Mechanism Of Action
ropeginterferon alfa-2b LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Hepatitis D - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit NTCP for Infectious Diseases and Unspecified Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
SVF-001 - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile
Product Description
Mechanism Of Action
vanitaracin A - Drug Profile
Product Description
Mechanism Of Action
VIR-2218 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VIR-3434 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hepatitis D - Dormant Projects
Hepatitis D - Product Development Milestones
Featured News & Press Releases
Jun 23, 2022: Albireo announces presentation of A2342 new data in Hepatitis
Jun 23, 2022: Treatment with Hepcludex (Bulevirtide) meets primary endpoint and achieves significant response in chronic hepatitis delta virus at 48 Weeks
Dec 21, 2021: Eiger BioPharmaceuticals announces first patient enrolled in LIMT-2: a phase 3 study of peginterferon lambda in patients with chronic hepatitis delta virus (HDV) infection
Dec 01, 2021: Eiger BioPharmaceuticals announces presentations on Lonafarnib at Upcoming HEP DART 2021 Meeting
Dec 01, 2021: Eiger BioPharmaceuticals announces presentations on Peginterferon Lambda at Upcoming HEP DART 2021 Meeting
Nov 19, 2021: Gilead submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an investigational treatment for people living with chronic hepatitis delta
Nov 02, 2021: Eiger concludes subject enrolment in Phase III HDV drug trial
Feb 24, 2021: VLP BioTech announces an immunotherapy designed for the treatment of chronic HBV/HDV infections
Nov 17, 2020: Eiger announces positive Peginterferon Lambda - Lonafarnib combination end of study results from phase 2 LIFT HDV study in late-breaker session at The Liver Meeting Digital Experience 2020
Nov 16, 2020: Eiger announces case studies demonstrating regression of liver fibrosis following 48 weeks of therapy with Peginterferon Lambda in patients with Chronic Hepatitis Delta Virus (HDV) Infection presented at The Liver Meeting Digital Experience 2020
Nov 02, 2020: Eiger announces abstracts highlighting Peginterferon Lambda and Lonafarnib in chronic hepatitis delta virus (HDV) infection accepted for presentation at The Liver Meeting Digital Experience 2020
Sep 17, 2020: MYR Pharmaceuticals launches HEPCLUDEX in Germany, France and Austria
Sep 03, 2020: European Commission (EC) Grants conditional Marketing Authorization (CMA) for MYR Pharmaceuticals HEPCLUDEX
Aug 31, 2020: Eiger announces Peginterferon Lambda - Lonafarnib combination end of treatment results from phase 2 LIFT HDV study in late breaker session at The Digital International Liver Congress 2020
Aug 04, 2020: MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hepatitis D, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hepatitis D - Pipeline by Albireo Pharma Inc, 2022
Hepatitis D - Pipeline by Antios Therapeutics Inc, 2022
Hepatitis D - Pipeline by CN Bio Innovations Ltd, 2022
Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, 2022
Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Hepatitis D - Pipeline by Gilead Sciences Inc, 2022
Hepatitis D - Pipeline by Globeimmune Inc, 2022
Hepatitis D - Pipeline by Huahui Anjian (Beijing) Biotechnology Co Ltd, 2022
Hepatitis D - Pipeline by Johnson & Johnson, 2022
Hepatitis D - Pipeline by Merck & Co Inc, 2022
Hepatitis D - Pipeline by PharmaEssentia Corp, 2022
Hepatitis D - Pipeline by Replicor Inc, 2022
Hepatitis D - Pipeline by Rodos BioTarget GmbH, 2022
Hepatitis D - Pipeline by SomaGenics Inc, 2022
Hepatitis D - Pipeline by Svenska Vaccinfabriken Produktion AB, 2022
Hepatitis D - Pipeline by Vir Biotechnology Inc, 2022
Hepatitis D - Dormant Projects, 2022

LIST OF FIGURES

Number of Products under Development for Hepatitis D, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications